Humanized anti-GPC-1 antibody
AssigneeIwate Medical University
InventorsTetsuji Naka, Satoshi Serada
Life of this patent
Estimating the term…
Abstract
The present disclosure provides a humanized antibody that specifically binds to Glypican-1 (GPC-1), and also provides technologies, methods, medicines, and the like related to the humanized antibody. In one aspect, the present disclosure provides a humanized anti-GPC-1 monoclonal antibody that has a high affinity for GPC-1 and has high internalization activity in GPC-1-positive cells. In another aspect, the present disclosure also provides a composition for preventing or treating Glypican-1-positive cancer that includes a complex of a humanized anti-GPC-1 monoclonal antibody and a medicine having cytotoxic activity.
Claims18
A humanized anti-GPC-1 antibody or an antigen-binding fragment thereof, comprising:
- heavy-chain CDRs 1 to 3 having amino acid sequences set forth in SEQ ID NOs:
- 28 to 30, respectively, and
- (a) light-chain CDRs 1 to 3 having amino acid sequences set forth in SEQ ID NOs:
- 31 to 33, respectively, or
- (b) light-chain CDRs 1 to 3 having amino acid sequences set forth in SEQ ID NOs:
- 37 to 39, respectively, or
- (c) light-chain CDRs 1 to 3 having amino acid sequences set forth in SEQ ID NOs:
- 40 to 42, respectively, or
- (d) light-chain CDRs 1 to 3 having amino acid sequences set forth in SEQ ID NOs:
- 43 to 45, respectively, or
- (e) light-chain CDRs 1 to 3 having amino acid sequences set forth in SEQ ID NOs:
- 49 to 51, respectively, or
- (f) light-chain CDRs 1 to 3 having amino acid sequences set forth in SEQ ID NOs:
- 55 to 57, respectively, or
- (g) light-chain CDRs 1 to 3 having amino acid sequences set forth in SEQ ID NOs:
- 58 to 60, respectively.
Dependencies are inferred from the claim text.